Company · founded 1988
Humanetics Corporation (United States)
Minneapolis, United States · humaneticscorp.com
- Citations, last 5 years
- 125
- Works, last 5 years
- 20
- h-index
- 18
- Scientists listed
- 1
- Grants since 2016
- 12
Grants received
2023–2025 · research · R43
Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis
Michael D Kaytor · Humanetics Corporation (United States) · funded by National Institutes of Health
2022–2027 · grant · PRMRP
Development of BIO 300 Injectable Suspension to Treat Radiation-Induced Lung Injury
Michael Kaytor · Humanetics Corporation (United States) · funded by Congressionally Directed Medical Research Programs
2021–2023 · grant · PRMRP
Treatment with BIO 300 to Mitigate COVID-19-Associated Acute Respiratory Distress Syndrome and Related Sequelae
Michael Kaytor · Humanetics Corporation (United States) · funded by Congressionally Directed Medical Research Programs
2020–2021 · contract · N01
SUPPLEMENTAL WORK-SARS-COV-2
Michael Kaytor · Humanetics Corporation (United States) · funded by National Institutes of Health
2020–2021 · contract · N01
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS
John Dykstra · Humanetics Corporation (United States) · funded by National Institutes of Health
2019–2025 · grant · JWMRP
Development of BIO 301 to Prevent Acute Radiation Syndrome and Mitigate the Delayed Effects of Acute Radiation Exposure
Michael Kaytor · Humanetics Corporation (United States) · funded by Congressionally Directed Medical Research Programs
2019–2020 · contract · N01
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS
Michael D Kaytor · Humanetics Corporation (United States) · funded by National Institutes of Health
2019–2022 · contract · N01
SUPPLEMENTAL WORK-SARS-COV-2
Michael Kaytor · Humanetics Corporation (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS
John Dykstra · Humanetics Corporation (United States) · funded by National Institutes of Health
2017–2022 · grant · PRMRP
Development of BIO 301: An Encapsulated Nanogenistein Therapy
Michael Kaytor · Humanetics Corporation (United States) · funded by Congressionally Directed Medical Research Programs
2016–2018 · research · R43
Development of BIO 300 as a MCM for lethal radiation pneumonitis/fibrosis
Isabel Lauren Jackson · Humanetics Corporation (United States) · funded by National Institutes of Health
2016–2019 · research · R43
Development of BIO 300 as a MCM for lethal radiation pneumonitis/fibrosis
Isabel Lauren Jackson · Humanetics Corporation (United States) · funded by National Institutes of Health